Oxford Capital, Seroba, Imperial Innovations & NESTA invest further £3.6 m in Veryan

12.03.10 - 17:07 ... source : Oxford Capital Partners

... Veryan closes £3.6m funding round to develop novel BioMimics 3D stent technology and announces the commencement of first-in human studies. Oxford, UK - 11th March 2010 Veryan Holdings Limited ("Veryan") announced today that it has secured additional funding totaling £3.6 million (US $5.4 million) from a syndicate of Investors led by new investor Seroba Kernel, a European life science venture capital firm, alongside existing investors Oxford Capital Partners Limited, Imperial Innovations and NESTA. The funds will be employed to finance further development activities and a pivotal clinical trial designed to show the clinical benefit of Veryans’ unique BioMimics 3D™ stent technology. Veryan technology Peripheral vascular disease treatment is one of the fastest growing segments of the cardiovascular device market, the potential market value is in excess of $1 billion. Existing stent technologies ...» Next (HTML)